

1. Record Nr.	UNINA9910590098503321
Autore	Kendrekar Pravin
Titolo	Drug Development for Malaria : Novel Approaches for Prevention and Treatment
Pubbl/distr/stampa	Newark : , : John Wiley & Sons, Incorporated, , 2022 ©2023
ISBN	3-527-83058-8 3-527-83060-X
Descrizione fisica	1 online resource (395 pages)
Disciplina	616.9362061
Soggetti	Electronic books.
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di contenuto	Cover -- Title Page -- Copyright -- Contents -- Part I Introduction -- Chapter 1 Chronology of Drug Development for Malaria -- 1.1 Introduction -- 1.1.1 Life Cycle of Malaria (Adapted from CDC) -- 1.2 Malaria - Erstwhile Memories -- 1.2.1 Progress Fighting Malaria -- 1.3 Current Chemotherapy Used to Treat Malaria -- 1.3.1 Current Combination Therapy -- 1.4 Drug Resistance of Antimalarial Drugs -- 1.4.1 Detection of Drug Resistance -- 1.5 Newer Drugs Approved for Malaria Treatment -- 1.6 Current Approaches to Developing a Malaria Vaccine -- 1.6.1 Hope for Vaccine Lies in the Parasite Itself -- 1.7 Conclusion: The Path Forward -- 1.7.1 RTS, S Vaccine: A New Tool with Potential for Africa -- References -- Part II Challenges and Opportunities in Malaria Therapy -- Chapter 2 Scientific Challenges and Treatment Opportunities in the Face of Shifting Malaria Epidemiology -- 2.1 Introduction -- 2.2 The Scientific Challenges Against Malarial Drug -- 2.3 Advances in Understanding and Managing Drug Resistance -- 2.3.1 Vector and Its Control -- 2.3.2 Parasite and Its Control -- 2.3.2.1 Malaria Vaccine -- 2.3.2.2 Antimalarial Drugs -- 2.4 Methods to Assess the Presence and Level of Drug Resistance -- 2.4.1 Therapeutic Efficacy of Antimalarial Drugs -- 2.4.2 Molecular Markers Associated with P. falciparum -- 2.5 Antimalarial Drugs Currently in Use and in the Pipeline -- 2.6 Future -- References -- Chapter 3 Emerging Formulation Technologies Against Malaria Resurgence -- List

of Abbreviations -- 3.1 Introduction -- 3.1.1 Major Pathological Hallmarks of Malaria -- 3.1.2 Current Treatment Strategies -- 3.2 Pitfalls of the Current Treatment Regimen -- 3.2.1 Drug Resistance -- 3.2.2 High Drug Dose -- 3.2.3 LongTerm Treatment -- 3.2.4 Recurrence and Reversion of Diseases -- 3.3 NanotechnologyBased Strategies for Targeting in Antimalarial Therapy. 3.3.1 Passive Targeting -- 3.3.2 Active Targeting -- 3.3.2.1 Hepatocyte Targeting -- 3.3.2.2 Erythrocyte Targeting -- 3.3.2.3 Brain Targeting -- 3.3.3 Rapid Diagnosis and Vector Control -- 3.4 Nano Formulations for Malarial Treatment -- 3.4.1 LipidBased Nanoplatfoms -- 3.4.1.1 Nanoemulsion -- 3.4.1.2 SelfEmulsifying Drug Delivery System (SEDDS) -- 3.4.1.3 Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs) -- 3.4.1.4 Liposome -- 3.4.2 PolymerBased Nanoplatfoms for Malaria -- 3.4.2.1 Nanoparticles -- 3.4.2.2 Nanocapsules -- 3.4.2.3 Dendrimers -- 3.4.2.4 Micelles -- 3.4.2.5 Polymeric Hydrogel Nanoparticles -- 3.4.2.6 Nanosuspension -- 3.4.3 Organized LayerbyLayer Assembly -- 3.4.4 Inorganic Nano architectonics -- 3.4.4.1 Metallic Platforms -- 3.4.4.2 Quantum Dots -- 3.4.4.3 Carbon Nanostructures -- 3.4.4.4 Bioceramics -- 3.4.5 Bio inspired Nanocarriers -- 3.4.5.1 Vaccines Based on Bioinspired Nanocarriers -- 3.4.5.2 Bioengineered Strategy Based on Erythrocytes -- 3.4.6 Protein-PeptideBased Drug Delivery System -- 3.4.7 Stimuli Responsive Platforms for Malaria -- 3.4.7.1 pHResponsive Formulations -- 3.4.7.2 ThermoResponsive Formulations -- 3.4.7.3 Redox State Responsive Substances -- 3.4.7.4 StimuliResponsive Liquid Crystalline Materials -- 3.5 Diagnostics -- 3.5.1 Stimuli Responsive Iron Oxide and Gold Nanoparticle Reagent System -- 3.5.2 Immunological Adjuvants -- 3.5.3 Nanofibers -- 3.6 Challenges in Clinical Translation of Nanomedicine -- 3.6.1 Biological Challenges -- 3.6.2 Biocompatibility and Safety -- 3.6.3 Challenges in Manufacturing ScaleUp and Reproducibility -- 3.6.4 Analytical Characterization and Quality Control Challenges of NanoFormulations -- 3.6.5 Regulatory Challenges -- 3.6.6 Other Challenges -- 3.7 Summary and Future Perspective -- 3.8 Conclusion -- Acknowledgments -- References. Chapter 4 Targeted Drug Delivery for Antimalarial Therapy -- 4.1 Introduction -- 4.2 Remodelling of ParasiteInfected Red Blood Cell (pRBC) -- 4.2.1 The Red Blood Cell Membrane (RBCM) -- 4.2.2 The Parasitophorous Vacuole Membrane (PVM) -- 4.2.3 The Parasite Plasma Membrane (PPM) -- 4.3 The Emergence of Resistance and Antimalarial Therapy Approach -- 4.4 Nanocarriers for Antimalarial Drug Delivery -- 4.4.1 Liposomes -- 4.4.2 Solid Lipid Nanoparticles (SLNs) -- 4.4.3 Nanostructured Lipid Carriers (NLCs) -- 4.4.4 Nanoemulsions (NEs) -- 4.4.5 Polymeric Nanoparticles -- 4.5 Targeted Antimalarial Drug Delivery Systems -- 4.5.1 Passive Drug Targeting with Conventional Nanocarriers -- 4.5.2 Active Drug Targeting with SurfaceModified Nanocarrier -- 4.6 Conclusion: Moving Towards the Future -- Acknowledgements -- References -- Chapter 5 The Imminent Threat of Antimalarial Drug Resistance -- 5.1 Introduction -- 5.2 Antimalarial Drugs: An Overview -- 5.3 The Evolution of CQ Resistance -- 5.3.1 Mechanism of Action of CQ -- 5.3.2 Basis of CQ Resistance -- 5.3.3 Prevalence of CQ Resistance -- 5.3.4 WHO Guidelines to Use CQ -- 5.4 Impact of Sulfadoxine-Pyrimethamine Resistance -- 5.4.1 Mechanism of Action of SP -- 5.4.2 SP Resistance -- 5.4.3 Distribution of DHPS and DHFR Mutation Across Globe -- 5.4.3.1 dhfr -- 5.4.3.2 dhps -- 5.4.4 WHO Guidelines to Use SP -- 5.4.4.1 IPTp Guidelines -- 5.4.4.2 IPTi Guidelines -- 5.5 ACT Resistance -- 5.5.1 Mechanism of Action of ART -- 5.5.2 ART Resistance and ACT Failure -- 5.5.3 WHO Guidelines -- 5.6 Conclusion: The Road Ahead -- References -- Chapter 6 Current

Therapies and New Drug Targets for the Future Drug Development of Drug Resistant Malaria -- 6.1 Introduction -- 6.2 Life Cycle of Plasmodium falciparum -- 6.3 Current Antimalarial Therapy and Their Shortcomings -- 6.4 Drug Targets for Current Antimalarial Therapy. 6.4.1 Drug Resistant Malaria and Identification of New Targets -- 6.4.1.1 Food Vacuole as Drug Targets -- 6.4.1.2 Shikimic Acid Pathway Targeting -- 6.4.1.3 Targeting Folate Pathway and Methionine Synthesis Pathway -- 6.4.1.4 Glycolytic Pathway Inhibition -- 6.4.2 Mitochondria as Drug Targets -- 6.4.2.1 Targeting Electron Transport Chain -- 6.4.2.2 Inhibition of Dihydroorotate Dehydrogenase -- 6.5 Future Drug Development for the Treatment of Malaria -- 6.5.1 Benefits of Nanocarriers -- 6.5.2 Lipid Based Drug Delivery -- 6.5.3 Liposomes (as Nanocarriers) -- 6.5.4 Nanostructured Lipid Carriers -- 6.5.5 Solid Lipid Nanocarriers -- 6.6 Conclusion -- References -- Part III Drug Development -- Chapter 7 Assays for Antimalarial Drug Discovery -- 7.1 Introduction -- 7.2 In Vitro Assays for Antimalarial Drug Discovery -- 7.2.1 Schizont Maturation Inhibition Assay (Microscopic Test) -- 7.2.2 In Vitro Micro Test Technique -- 7.2.3 Radioisotope Assay -- 7.2.4 Colorimetric Assay (Plasmodium Lactate Dehydrogenase Assay [pLDH]) -- 7.2.5 ELISA Based Methods -- 7.2.5.1 DELI Assay -- 7.2.5.2 Assay Based on Histidine Rich Protein II (HRP II) of P. falciparum -- 7.2.6 Flow Cytometry -- 7.2.7 Fluorometric Assay -- 7.2.8 Hematin Formation (Haemozoin Test) -- 7.2.9 Drug Interaction Assay and Isobologram Analysis -- 7.2.10 PCR Based Methods -- 7.2.11 In Vitro Assays Targeting Exoerythrocytic and Sexual Stages of the Parasite -- 7.2.11.1 Exoerythrocytic Schizontocidal Assay -- 7.2.11.2 Exflagellation Assay -- 7.3 In Vivo Assays for Antimalarial Drug Discovery -- 7.3.1 Peters' 4Day Test -- 7.3.2 Dose Ranging Full 4Day Test -- 7.3.3 Onset/Recrudescence Test -- 7.3.4 Preventive Test -- 7.3.5 Curative Test -- 7.3.6 Hill's Test for Causal Prophylaxis and Residual Activity -- 7.3.7 Assays with P. berghei Green Fluorescent Protein (PbGFP). 7.3.8 Assays Employing Immunocompromised Mice -- 7.3.9 Primate Models for In Vivo Studies -- 7.3.10 Sporontocidal Assays -- 7.3.11 Antisporozoite Assay -- 7.4 Ex Vivo Assays for Antimalarial Drug Discovery -- 7.5 Assays for Assessment of In Vitro Toxicity -- 7.5.1 MTT Assay -- 7.5.2 XTT Assay -- 7.5.3 LDH (Lactate Dehydrogenase) Assay -- 7.5.4 Protein Content Assay -- 7.5.5 Neutral Red Uptake Assay (NRU) -- 7.6 Assays for Assessment of In Vivo Toxicity -- 7.6.1 Acute Toxicity -- 7.6.1.1 Limit Test of Lorke -- 7.6.1.2 Up and Down Procedure -- 7.6.2 Chronic Toxicity -- 7.7 Conclusion -- References -- Chapter 8 Aminoacyl tRNA Synthetases as Malarial Drug Targets: A Structural Biology Perspective -- 8.1 Introduction -- 8.2 Pf/PvaaRSs -- 8.2.1 Pf/Pv Genome -- 8.2.2 Aminoacyl tRNA Synthetases (aaRSs) -- 8.3 Aminoacyl tRNA Synthetases as Druggable Targets -- 8.4 Biochemical Screening of Drug Libraries -- 8.4.1 Colorimetric Assays -- 8.4.2 Enzyme Coupled Assays -- 8.4.3 Luciferase Assay -- 8.4.4 Assay to Test Synthetic as Well as Proofreading Activity -- 8.5 Structurally Validated Pf/PvaaRSs as Drug Targets -- 8.5.1 Lysyl tRNA Synthetase (KRS) -- 8.5.2 Prolyl tRNA Synthetase -- 8.6 Potential Drug Targets Pf/PvaaRSs -- 8.6.1 Leucyl tRNA Synthetase (LRS) -- 8.7 Arginyl tRNA Synthetase (RRS) -- 8.7.1 Tryptophanyl tRNA Synthetase (WRS) -- 8.7.2 Tyrosyl tRNA Synthetase -- 8.8 Others -- 8.9 Conclusion: The Road Ahead -- References -- Chapter 9 Natural Products as a Source for Antimalarial Drug Development Process - An Overview -- 9.1 Introduction -- 9.2 Phytochemicals as Antimalarial Agents: Recent Developments -- 9.2.1 Alkaloids -- 9.2.2 Terpenes -- 9.2.2.1 Sesquiterpene Lactones -- 9.2.2.2 Diterpenes -- 9.2.2.3

Triterpenes -- 9.2.2.4 Steroids and Others -- 9.2.3 Polyphenols --
9.2.3.1 Biflavonoids -- 9.2.3.2 Prenylated Flavonoids -- 9.2.3.3 Other
Flavonoids.

9.3 Traditional System of Medicine and Malaria.

2. Record Nr.	UNINA9910815827303321
Autore	Moore Alison M.
Titolo	Sexual myths of modernity : sadism, masochism, and historical teleology // Alison M. Moore
Pubbl/distr/stampa	Lanham : , : Lexington Books, , [2016] ©2016
ISBN	1-4985-3073-7
Descrizione fisica	1 online resource (289 p.)
Disciplina	306.77/5
Soggetti	Sadomasochism - History Political violence - History Teleology - History
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	Introduction -- Perversion, gender, and nature in nineteenth-century visions of pleasure, violence, and civilization -- Psychoanalytic sexual teleology -- Civilized perversions in interwar europe -- Critical myths of nazi perversion : sadism, homosexuality, enlightenment, and barbarism -- The polarizing myth of "real" sadists and masochists -- Fantasies of the "sadiconazista" -- Nazi sexual pathology in historiography -- Genocidal pleasures -- Bibliography -- About the author.
Sommario/riassunto	This ambitious and wide-ranging study of late-nineteenth- and twentieth-century culture and thought transverses texts of evolutionary biology, psychiatry, psychoanalysis, political propaganda, fiction, historiography of Nazism, and scholarship on comparative genocide to analyze the notion that mass violence is sexually motivated.